Mongolia

Mongolia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
4.28 (3.88 - 4.70) 2019 Modelled IHME
4.44 (4.02 - 4.86) 2018 Modelled IHME
4.55 (4.08 - 5.03) 2017 Modelled IHME
4.6 (4.12 - 5.03) 2016 Modelled IHME
4.65 (4.14 - 5.15) 2015 Modelled IHME
4.75 (4.22 - 5.24) 2014 Modelled IHME
4.9 (4.34 - 5.38) 2013 Modelled IHME
5.07 (4.47 - 5.56) 2012 Modelled IHME
5.22 (4.60 - 5.75) 2011 Modelled IHME
5.34 (4.67 - 5.89) 2010 Modelled IHME
5.42 (4.75 - 5.99) 2009 Modelled IHME
5.48 (4.81 - 6.05) 2008 Modelled IHME
5.54 (4.85 - 6.11) 2007 Modelled IHME
5.59 (4.88 - 6.20) 2006 Modelled IHME
5.65 (4.88 - 6.31) 2005 Modelled IHME
5.72 (4.95 - 6.40) 2004 Modelled IHME
5.78 (4.98 - 6.49) 2003 Modelled IHME
5.85 (4.98 - 6.57) 2002 Modelled IHME
5.92 (5 - 6.69) 2001 Modelled IHME
6.01 (5.01 - 6.83) 2000 Modelled IHME
6.13 (5.11 - 6.95) 1999 Modelled IHME
6.3 (5.28 - 7.14) 1998 Modelled IHME
6.48 (5.48 - 7.32) 1997 Modelled IHME
6.63 (5.65 - 7.51) 1996 Modelled IHME
6.73 (5.70 - 7.68) 1995 Modelled IHME
6.78 (5.71 - 7.73) 1994 Modelled IHME
6.83 (5.72 - 7.81) 1993 Modelled IHME
6.87 (5.72 - 7.90) 1992 Modelled IHME
6.9 (5.71 - 7.99) 1991 Modelled IHME
6.91 (5.70 - 8.12) 1990 Modelled IHME
10.8 (8.80 - 13.31) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.29 (0.20 - 0.36) 2019 Modelled IHME
0.31 (0.21 - 0.41) 2018 Modelled IHME
0.33 (0.22 - 0.43) 2017 Modelled IHME
0.32 (0.22 - 0.42) 2016 Modelled IHME
0.31 (0.21 - 0.40) 2015 Modelled IHME
0.33 (0.22 - 0.42) 2014 Modelled IHME
0.35 (0.24 - 0.46) 2013 Modelled IHME
0.4 (0.27 - 0.51) 2012 Modelled IHME
0.44 (0.29 - 0.58) 2011 Modelled IHME
0.49 (0.32 - 0.64) 2010 Modelled IHME
0.56 (0.36 - 0.73) 2009 Modelled IHME
0.64 (0.43 - 0.84) 2008 Modelled IHME
0.73 (0.49 - 0.95) 2007 Modelled IHME
0.8 (0.53 - 1.03) 2006 Modelled IHME
0.82 (0.55 - 1.07) 2005 Modelled IHME
0.82 (0.54 - 1.07) 2004 Modelled IHME
0.81 (0.52 - 1.07) 2003 Modelled IHME
0.79 (0.50 - 1.06) 2002 Modelled IHME
0.78 (0.48 - 1.06) 2001 Modelled IHME
0.78 (0.47 - 1.06) 2000 Modelled IHME
0.79 (0.49 - 1.08) 1999 Modelled IHME
0.84 (0.53 - 1.12) 1998 Modelled IHME
0.9 (0.59 - 1.19) 1997 Modelled IHME
0.99 (0.66 - 1.29) 1996 Modelled IHME
1.09 (0.75 - 1.41) 1995 Modelled IHME
1.29 (0.90 - 1.66) 1994 Modelled IHME
1.65 (1.13 - 2.14) 1993 Modelled IHME
2.12 (1.42 - 2.80) 1992 Modelled IHME
2.69 (1.78 - 3.60) 1991 Modelled IHME
3.3 (2.18 - 4.48) 1990 Modelled IHME
1.72 (1.14 - 2.57) 2015 Modelled WHO
0.5 2009 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
30 (22 - 39) 2019 Modelled IHME
30 (23 - 40) 2018 Modelled IHME
30 (23 - 39) 2017 Modelled IHME
30 (23 - 39) 2016 Modelled IHME
30 (23 - 39) 2015 Modelled IHME
31 (23 - 39) 2014 Modelled IHME
31 (23 - 39) 2013 Modelled IHME
31 (23 - 39) 2012 Modelled IHME
31 (24 - 39) 2011 Modelled IHME
31 (24 - 39) 2010 Modelled IHME
31 (24 - 39) 2009 Modelled IHME
31 (24 - 40) 2008 Modelled IHME
31 (24 - 40) 2007 Modelled IHME
31 (24 - 40) 2006 Modelled IHME
32 (24 - 40) 2005 Modelled IHME
32 (24 - 41) 2004 Modelled IHME
33 (25 - 42) 2003 Modelled IHME
33 (25 - 43) 2002 Modelled IHME
34 (26 - 44) 2001 Modelled IHME
35 (26 - 44) 2000 Modelled IHME
35 (27 - 45) 1999 Modelled IHME
35 (27 - 45) 1998 Modelled IHME
35 (27 - 45) 1997 Modelled IHME
35 (27 - 45) 1996 Modelled IHME
35 (27 - 45) 1995 Modelled IHME
35 (27 - 45) 1994 Modelled IHME
35 (27 - 45) 1993 Modelled IHME
35 (26 - 44) 1992 Modelled IHME
34 (26 - 44) 1991 Modelled IHME
34 (25 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
97 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
89 2005 Survey/reported WHO/UNICEF
98 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
98 2002 Survey/reported WHO/UNICEF
98 2001 Survey/reported WHO/UNICEF
96 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
96 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
98 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
98 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
93 2000 Survey/reported WHO/UNICEF
92 1999 Survey/reported WHO/UNICEF
91 1998 Survey/reported WHO/UNICEF
88 1997 Survey/reported WHO/UNICEF
93 1996 Survey/reported WHO/UNICEF
88 1995 Survey/reported WHO/UNICEF
67 1994 Survey/reported WHO/UNICEF
69 1993 Survey/reported WHO/UNICEF
47 1992 Survey/reported WHO/UNICEF
18 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
9.34 (7.16 - 12.08) 2019 Modelled IHME
9.4 (7.25 - 12.30) 2018 Modelled IHME
9.49 (7.26 - 12.61) 2017 Modelled IHME
9.67 (7.43 - 12.78) 2016 Modelled IHME
9.88 (7.34 - 13.19) 2015 Modelled IHME
10.11 (7.57 - 13.37) 2014 Modelled IHME
10.4 (7.81 - 13.61) 2013 Modelled IHME
10.67 (8.11 - 13.80) 2012 Modelled IHME
10.88 (8.28 - 13.95) 2011 Modelled IHME
10.96 (8.33 - 14.12) 2010 Modelled IHME
10.84 (8.26 - 13.85) 2009 Modelled IHME
10.53 (8.07 - 13.33) 2008 Modelled IHME
10.15 (7.82 - 12.71) 2007 Modelled IHME
9.79 (7.55 - 12.20) 2006 Modelled IHME
9.58 (7.39 - 11.97) 2005 Modelled IHME
9.47 (7.42 - 11.73) 2004 Modelled IHME
9.37 (7.41 - 11.49) 2003 Modelled IHME
9.29 (7.34 - 11.41) 2002 Modelled IHME
9.23 (7.37 - 11.33) 2001 Modelled IHME
9.21 (7.35 - 11.34) 2000 Modelled IHME
9.2 (7.37 - 11.33) 1999 Modelled IHME
9.2 (7.40 - 11.39) 1998 Modelled IHME
9.2 (7.39 - 11.43) 1997 Modelled IHME
9.2 (7.37 - 11.47) 1996 Modelled IHME
9.2 (7.31 - 11.50) 1995 Modelled IHME
9.19 (7.33 - 11.51) 1994 Modelled IHME
9.18 (7.35 - 11.50) 1993 Modelled IHME
9.16 (7.29 - 11.45) 1992 Modelled IHME
9.15 (7.29 - 11.41) 1991 Modelled IHME
9.13 (7.26 - 11.42) 1990 Modelled IHME
6.4 (4.30 - 7.90) 2015 Modelled Blach et al, 2017
7.5 (6.10 - 10.90) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
10.8 (8.70 - 15.60) 2014 Modelled Gower et al, 2014
10.8 (8.70 - 15.60) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
30 (21 - 38) 2019 Modelled IHME
30 (21 - 38) 2018 Modelled IHME
30 (21 - 38) 2017 Modelled IHME
30 (22 - 38) 2016 Modelled IHME
30 (22 - 38) 2015 Modelled IHME
30 (22 - 38) 2014 Modelled IHME
30 (22 - 39) 2013 Modelled IHME
30 (22 - 39) 2012 Modelled IHME
31 (23 - 39) 2011 Modelled IHME
31 (23 - 39) 2010 Modelled IHME
31 (23 - 39) 2009 Modelled IHME
31 (23 - 40) 2008 Modelled IHME
31 (23 - 40) 2007 Modelled IHME
31 (23 - 40) 2006 Modelled IHME
31 (23 - 40) 2005 Modelled IHME
31 (23 - 40) 2004 Modelled IHME
31 (22 - 40) 2003 Modelled IHME
30 (22 - 39) 2002 Modelled IHME
30 (22 - 39) 2001 Modelled IHME
30 (21 - 38) 2000 Modelled IHME
29 (21 - 38) 1999 Modelled IHME
29 (21 - 38) 1998 Modelled IHME
29 (21 - 38) 1997 Modelled IHME
29 (21 - 38) 1996 Modelled IHME
29 (21 - 39) 1995 Modelled IHME
30 (21 - 39) 1994 Modelled IHME
30 (21 - 39) 1993 Modelled IHME
30 (22 - 40) 1992 Modelled IHME
31 (22 - 40) 1991 Modelled IHME
31 (22 - 41) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2020

Prevalence (national)

Modelled

HBV (HBsAg+)
4.28 (%)
2019
(3.88 - 4.7(%))
IHME
HCV (RNA/cAg+)
9.34 (%)
2019
(7.16 - 12.08(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
987
2019
(689 - 1,351)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,044
2019
(763 - 1,389)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.29 (%)
2019, latest modelled
(0.20 - 0.36(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
98 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Partners